Amgen, Pfizer’s Hospira Settle Neulasta Cancer Drug Patent Suit

Amgen Inc. and Pfizer Inc.'s Hospira settled a patent-infringement lawsuit over Hospira’s proposed biosimilar version of Neulasta, the blockbuster cancer treatment that had U.S. sales of more than $1.5 billion in 2021.

No details of the settlement were made available in the agreement, which Judge Colm F. Connolly approved Monday in the U.S. District Court for the District of Delaware.

Amgen filed the suit in February 2020, seeking royalties from sales of Hospira’s cheaper version for allegedly infringing a patent that covers a process for purifying proteins that Bloomberg Law estimates will expire in September 2024.

Biosimilars are ...